Search results for "Oncostatin M"

showing 9 items of 9 documents

Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells

1998

AbstractOncostatin M (OSM) is a potent modulator of human lung-derived epithelial cell function. This cytokine binds two distinct receptor complexes: type I OSM receptor which is also a functional receptor for leukemia inhibitory factor (LIF), and type II OSM-specific receptor. The role of these two distinct receptors in mediating the response of individual cell types to OSM has not been delineated. In contrast to LIF, OSM induces synthesis of α1-antichymotrypsin and α1-antiproteinase inhibitor in lung-derived epithelial cells. The differential responsiveness to LIF and OSM suggested that the response of lung epithelial cells to OSM may be mediated by the OSM-specific receptor. Therefore, w…

Cell typemedicine.medical_treatmentTransforming growth factor β1Respiratory SystemBronchial epitheliumBiophysicsBronchiOncostatin MInterleukin 1 receptor type IILeukemia Inhibitory FactorBiochemistryDexamethasoneAntigens CDStructural BiologyCytokine Receptor gp130GeneticsmedicineHumansReceptors CytokineReceptorLungMolecular BiologyLymphokinesMembrane GlycoproteinsbiologyInterleukin-6ChemistryfungiOncostatin MOncostatin M receptorEpithelial CellsReceptors Oncostatin MCell BiologyGrowth InhibitorsCell biologyInterleukin 31CytokineGene Expression Regulationbiology.proteinCancer researchCytokinesInflammation MediatorsPeptidesLeukemia inhibitory factorFEBS Letters
researchProduct

Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to eto…

1999

BACKGROUND The mechanisms of drug resistance associated with advanced, hormone-independent prostate carcinoma are poorly understood. The human prostate carcinoma PC-3 cell line, derived from a metastatic tumor and lacking androgen receptors, represents a useful model to investigate drug resistance. METHODS The effects of oncostatin M (OM), antiinterleukin-6 (IL-6) treatment, or interference with the gp130-mediated signaling on etoposide- or cisplatin-mediated cytotoxicity were investigated. RESULTS Both endogenous and exogenous IL-6 and exogenous OM up-regulated cell growth and enhanced resistance of PC-3 tumor cells to both etoposide and cisplatin. The influence of IL-6 is controlled by tr…

MaleCancer Researchmedicine.drug_classAntineoplastic AgentsOncostatin MBiologyCell surface receptorAntigens CDCyclohexenesmedicineCytokine Receptor gp130Tumor Cells CulturedHumansReceptorEtoposideEtoposideMembrane GlycoproteinsCell growthInterleukin-6TerpenesOncostatin MProstatic NeoplasmsGlycoprotein 130Receptor antagonistAntineoplastic Agents PhytogenicGenisteinOncologyDrug Resistance NeoplasmCancer researchbiology.proteinMonoterpenesSignal transductionCisplatinPeptidesmedicine.drugSignal Transduction
researchProduct

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma

2014

Interleukin (IL)-31A binds to an heterodimer composed of IL-31 receptor A (IL-31RA) and Oncostatin M Receptor (OSMR). The IL-31/IL-31R complex is involved in the pathogenesis of various skin diseases, including cutaneous T-cell lymphoma. No information is available on the relations between the IL-31/IL-31R complex and B-cell lymphoma. Here we have addressed this issue in follicular lymphoma (FL), a prototypic germinal center(GC)-derived B-cell malignancy. IL-31 enhanced primary FL cell proliferation through IL-31R-driven signal transducer and activator of transcription factor 1/3 (STAT1/3), extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation. In contrast, GC B cells d…

MaleSTAT3 Transcription Factormedicine.medical_specialtyCancer ResearchPrimary Cell CultureFollicular lymphomaBiologyParacrine signallingCytosolCell-Derived MicroparticlesInternal medicinemedicineHumansProtein IsoformsPhosphorylationAutocrine signallingLymphoma FollicularCell ProliferationMitogen-Activated Protein Kinase 1B-LymphocytesMitogen-Activated Protein Kinase 3Gene Expression Regulation LeukemicInterleukinsMicrovesicleMedicine (all)Cell MembraneB-LymphocyteGerminal centerOncostatin M receptorInterleukinProtein IsoformReceptors InterleukinHematologyInterleukinMiddle Agedmedicine.diseaseGerminal CenterMolecular biologyCell-Derived MicroparticleEndocrinologySTAT1 Transcription FactorAnesthesiology and Pain MedicineOncologyFemaleSignal transductionNeoplasm GradingProto-Oncogene Proteins c-aktHumanSignal Transduction
researchProduct

Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis

1998

T HE INTERLEUKIN-6 (IL-6) family of cytokines acts via receptor complexes that contain at least one subunit of the signal transducing protein gp130.[1][1] The family comprises IL-6, IL-11, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), leukemia inhibitory factor (LIF), and oncostatin M

Models Molecularendocrine systemmedicine.medical_specialtyRecombinant Fusion ProteinsImmunologyMice TransgenicLeukemia inhibitory factor receptorOncostatin MBiologyCiliary neurotrophic factorBiochemistryDesigner DrugsMiceStructure-Activity RelationshipAntigens CDInternal medicineCytokine Receptor gp130medicineAnimalsHumansInterleukin 6Membrane GlycoproteinsInterleukin-6Oncostatin MOncostatin M receptorCell DifferentiationReceptors InterleukinCell BiologyHematologyHematopoietic Stem CellsGlycoprotein 130Receptors Interleukin-6Molecular biologyHematopoiesisEndocrinologyLiverSolubilitybiology.proteinSignal transductionPeptidesLeukemia inhibitory factorSpleenBlood
researchProduct

Sequential Hepatogenic Transdifferentiation of Adipose Tissue-Derived Stem Cells: Relevance of Different Extracellular Signaling Molecules, Transcrip…

2009

Adipose tissue contains a mesenchymal stein cell (MSC) population Known as adipose-derived stein cells (ASCs) capable of differentiating into different cell types. Our aim was to induce hepatic transdifferentiation of ASCs by sequential exposure to several combinations of cytokines, growth factors, and hormones. The most efficient hepatogenic protocol includes fibroblastic growth factors (FGF) 2 and 4 and epidermal growth factor (EGF) (step 1), hepatocyte growth factor (HGF), FGF2, FGF4, and nicotinamide (Nic) (step 2), and oncostatin M (OSM), dexamethasone (Dex), and insulin-tranferrin-selenium (step 3). This protocol activated transcription factors [GATA6, Hex, CCAAT/enhancer binding prot…

NiacinamideCellular differentiationBiomedical Engineeringlcsh:MedicineOncostatin MBiologyDexamethasoneSeleniumEpidermal growth factorEnhancer bindingHumansInsulinCells CulturedHepatocyte differentiationTransplantationHepatocyte Growth FactorGene Expression Profilinglcsh:RTransdifferentiationTransferrinMesenchymal Stem CellsHep G2 CellsCell BiologyFlow CytometryMolecular biologyCell biologyFibroblast Growth FactorsAdipose TissueHepatocyte Nuclear Factor 4Hepatocyte nuclear factor 4 alphaCell TransdifferentiationHepatocytesStem cellSignal TransductionTranscription FactorsAdult stem cellCell Transplantation
researchProduct

A New Type of Cytokine Receptor Antagonist Directly Targeting gp130

1998

The interleukin-6-type family of cytokines bind to receptor complexes that share gp130 as a common signal-transducing subunit. So far, receptor antagonists for interleukin-6-type cytokines have been constructed that still bind to the specific ligand binding subunit of the receptor complex, but have lost the ability to stimulate gp130. Such receptor antagonists compete for a specific receptor of a member of the cytokine family. Interleukin-6 only binds to gp130 when complexed with the interleukin-6 receptor that exists as a membrane bound and soluble molecule. Here we have constructed fusion proteins that consist of the soluble form of the human interleukin-6 receptor covalently linked to in…

Receptor complexRecombinant Fusion ProteinsNerve Tissue ProteinsOncostatin MBiologyLeukemia Inhibitory FactorBiochemistryAntigens CDCytokine Receptor gp130Enzyme-linked receptorHumansPoint Mutation5-HT5A receptorCiliary Neurotrophic FactorMolecular BiologyProtease-activated receptor 2Common gamma chainLymphokinesMembrane GlycoproteinsDose-Response Relationship DrugJanus kinase 1Interleukin-6digestive oral and skin physiologyCell BiologyReceptors Interleukin-6Growth Inhibitorsbiological factorsBiochemistryInterleukin-21 receptorCytokinesPeptidesCytokine receptorProtein BindingJournal of Biological Chemistry
researchProduct

The Soluble Interleukin-6 Receptora

2006

biologyChemistryGeneral NeuroscienceLymphokineOncostatin MCiliary neurotrophic factorMolecular biologyGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of Sciencebiology.proteinLeukemia Inhibitory Factor Receptor alpha SubunitInterleukin 6ReceptorPeptide sequenceLeukemia inhibitory factorAnnals of the New York Academy of Sciences
researchProduct

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

2001

Signal transduction in response to interleukin-6 (IL-6) requires binding of the cytokine to its receptor (IL-6R) and subsequent homodimerization of the signal transducer gp130. The complex of IL-6 and soluble IL-6R (sIL-6R) triggers dimerization of gp130 and induces responses on cells that do not express membrane bound IL-6R. Naturally occurring soluble gp130 (sgp130) can be found in a ternary complex with IL-6 and sIL-6R. We created recombinant sgp130 proteins that showed binding to IL-6 in complex with sIL-6R and inhibited IL-6/sIL-6R induced proliferation of BAF/3 cells expressing gp130. Surprisingly, sgp130 proteins did not affect IL-6 stimulated proliferation of BAF/3 cells expressing …

biologySoluble Glycoprotein 130medicine.medical_treatmentOncostatin MTransfectionGlycoprotein 130BiochemistryMolecular biologyCytokinebiology.proteinmedicineSignal transductionLeukemia inhibitory factorTernary complexEuropean Journal of Biochemistry
researchProduct

Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha1-proteinase inhibitor synthesis in human lung-derived …

1998

Interleukin 6 (IL-6), oncostatin M (OSM) and leukaemia-inhibitory factor (LIF) share a common signal-transducing subunit in each of their receptors and thus mediate an overlapping spectrum of biological activities. Although all of these cytokines stimulate the production of α1-proteinase inhibitor (α1-PI) in hepatocyte-derived cells, only OSM is able to up-regulate levels of this inhibitor in epithelial cells originating from the lung. In this study we characterized human lung-derived epithelial-like HTB58 cells for their ability to synthesize α1-PI after treatment with IL-6, OSM and LIF. The results demonstrate that the resistance of HTB58 cells to the effects of IL-6 and LIF was not becau…

medicine.medical_specialtyendocrine systemProtein subunitBlotting WesternOncostatin MInhibitory postsynaptic potentialBiochemistryLeukemia Inhibitory FactorInternal medicinemedicineTumor Cells CulturedHumansInterleukin 6ReceptorMolecular BiologyLungLymphokinesbiologyChemistryInterleukin-6fungiOncostatin MOncostatin M receptorEpithelial CellsCell BiologyGlycoprotein 130Blotting NorthernGrowth InhibitorsCell biologyInterleukin 31Endocrinologyalpha 1-Antitrypsinbiology.proteinPeptidesResearch ArticleThe Biochemical journal
researchProduct